Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study.
Tobias MoserGeorg ZimmermannAnna BaumgartnerThomas BergerGabriel BstehFranziska Di PauliChristian EnzingerElisabeth FertlThomas HellerStefan KoppiPaulus S RommerGeorg SafoschnikThomas Seifert-HeldRobert StepanskyJohann SellnerPublished in: Journal of neurology (2023)
The number of NAT-PML cases is decreasing over time. While many patients accumulated severe persistent neurological deficits compared to pre-PML, inflammatory MS-related disease activity after PML recovery was rare.
Keyphrases
- disease activity
- multiple sclerosis
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- rheumatoid arthritis patients
- ejection fraction
- newly diagnosed
- ankylosing spondylitis
- chronic kidney disease
- mass spectrometry
- peritoneal dialysis
- oxidative stress
- juvenile idiopathic arthritis
- prognostic factors
- traumatic brain injury
- ms ms
- patient reported outcomes
- cross sectional